InnoCare Completes Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
We are committed to discovering, developing and commercializing best-in-class and/or first-in-class drugs for the treatment of cancer and autoimmune diseases. Led by a world-class management team of seasoned industry executives, we have built a fully integrated biopharmaceutical platform with strong in-house R&D capabilities, including drug target identification and verification, preclinical evaluation, clinical trial design and execution, drug manufacturing and quality control, and commercialization.
We have built a fully integrated biopharmaceutical platform that allows us to oversee all aspects of the drug development cycle. By having all functions in-house, we are able to improve operational efficiency and control quality every step of the way.
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in China
InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China